Market Overview

UPDATE: Morgan Stanley Reiterates on CVS/Caremark Following Acquisition of Coram

Related CVS
Fast Money Picks For December 23: Gilead Sciences, Starbucks, CVS Health
Bank Of America Raises CVS Health Price Target
Making Money With Charles Payne: 12/5/14 (Fox Business)

In a report published Friday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on CVS/Caremark Corporation (NYSE: CVS), but removed the $65.00 price target.

In the report, Morgan Stanley noted, “CVS' $2.1 billion acquisition of Coram, Apria's home infusion business should help solidify CVS' position in the HC continuum and in enhancing its relationships with health systems and ACOs in our view. Importantly, we don't think deal stands in way of supply chain/sourcing partnership.”

CVS/Caremark closed on Wednesday at $66.76.

Latest Ratings for CVS

DateFirmActionFromTo
Dec 2014SunTrust Robinson HumphreyUpgradesBuy
Dec 2014BarclaysMaintainsOverweight
Dec 2014JP MorganMaintainsOverweight

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: Morgan Stanley Ricky R. GoldwasserAnalyst Color Price Target Analyst Ratings

 

Related Articles (CVS)

Around the Web, We're Loving...

Get Benzinga's Newsletters